Neural Stem Cells Show Early Promise in Phase 1 Trial as Treatment for Parkinson’s
Patients with moderate-to-severe Parkinson’s disease who received human neural stem cells in their brain as part of a Phase 1…
Articles by Patricia Inácio, PhD
Additional Blood Cell Monitoring Added to Tozadenant Trials Following Adverse Events
Acorda Therapeutics announced that it will now monitor blood cell counts on a weekly basis in Parkinson’s disease patients enrolled…
Parkinson’s Patients Sought for Phase 2a Trial Testing Repurposed Therapy Nilotinib
A new Phase 2a clinical trial, funded by The Michael J. Fox Foundation (MJFF), is now recruiting Parkinson’s disease…
Carbidopa Reduced Tumor Growth in Lab Studies of Cancer
Carbidopa, a medicine approved for the treatment of Parkinson’s disease, also has shown anti-cancer effects in lab-grown human cells and…
Toxoplasma Brain Parasite Modulates Signaling Pathways Common in Parkinson’s Disease
Infection with the brain parasite Toxoplasma gondii may increase the likelihood for certain brain disorders, including Parkinson’s and Alzheimer’s disease, a…
Another Protein Plays a Role in Spreading Harmful Alpha-synuclein in Parkinson’s, Mouse Study Shows
Scientists have linked the clumping of alpha-synuclein protein to Parkinson’s disease, and a study in mice indicates that the clumps…
Common Antiseptic Ingredients Disrupt Mitochondria’s Function, Impair Hormone Response, Study Finds
Commonly used in household products, the antimicrobial agents known as quaternary ammonium compounds, or “quats,” were found to inhibit mitochondria…
AC Immune Develops Antibodies That Target Two Proteins in Parkinson’s Disease
AC Immune has developed antibodies against two proteins that are key players in the neurodegeneration underlying Parkinson’s and other neurological diseases.
AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
AstraZeneca has partnered with Takeda Pharmaceutical to develop and commercialize the alpha-synuclein antibody MEDI1341 for…
Gocovri Approved by FDA as 1st Treatment for Levodopa-induced Dyskinesia in Parkinson’s Patients
The first treatment for levodopa-induced dyskinesia — the involuntary and jerky movements that afflict most Parkinson’s disease patients on this…